# Study of BAY1834942 in Patients With Solid Tumors

> **NCT03596372** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 30 (actual)

## Conditions studied

- Advanced CEACAM6-expressing Solid Tumors

## Interventions

- **DRUG:** BAY1834942

## Key facts

- **NCT ID:** NCT03596372
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2020-11-16
- **Final completion:** 2021-02-22
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596372, "Study of BAY1834942 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03596372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*